NewsRoom Articles - Page 2 of 206

WednesdayJun 11, 2025 10:30 am

Adageis Allows Healthcare Providers Maximum Value-Based Care Revenue with Simplicity and Visibility

The company offers a simple, AI-powered platform that helps providers identify their most valuable services, bringing clarity to complex insurance contracts, and highlighting where clinics can optimize revenue. The platform’s AI analytics help to identify high-risk patients and close care gaps efficiently, while letting providers track financial performance over time, aligning income with quality of care. Adageis continues to grow and expects to cover 580,000 patient lives by Q2 2025 and reach $100,000 in monthly recurring revenue. As healthcare shifts further toward value-based care, one challenge continues to frustrate providers: understanding how care quality translates into financial outcomes. Adageis, a…

WednesdayJun 11, 2025 9:45 am

Smart Hospitality: SkyTech Robots and the Future of U.S. Service Innovation Through AI

As the world watches Foxconn and NVIDIA deploy smart robotics in Taiwan’s cutting-edge hospitals, the same technology driven future is quietly taking shape across the American hospitality industry. Led by companies like SkyTech Automated Solutions, a wholly owned subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF). Foxconn's recent unveiling of its NVIDIA-powered hospital robots signals a monumental shift: combining real-time AI with robotics to improve labor efficiency, safety, and service personalization. The smart hospital model represents not just a technological leap, but a redefinition of how service delivery is imagined in labor-intensive environments. SkyTech is bringing that same revolution to the…

WednesdayJun 11, 2025 9:00 am

Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline. The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL. Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations. Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways. With approximately $19.7 million in cash and equivalents, the company is funded through at least mid-2026 to support…

TuesdayJun 10, 2025 10:00 am

Celebrity Announcements of Breast Cancer Underscore Increasing Prevalence in Younger Women

Many young celebrities have recently announced that they have been diagnosed with breast cancer. This is a clear pointer to the public that cases of this disease among younger women not yet 50 years of age are rising in America. For example, Jessie J, a pop singer aged 37, took to Instagram last week to reveal her intention to under surgery in a few weeks after her early-stage diagnosis of breast cancer. Katie Thurston, who starred in “The Bachelorette,” has been active on social media sharing about her journey after being diagnosed with stage-four breast cancer. She is 34 years…

FridayJun 06, 2025 12:00 pm

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25 as U.S. Expansion Advances

The company’s non-invasive fingerprint drug screening system uses fingerprint sweat to screen for drugs such as cannabis, cocaine, methamphetamine, and opiates. Results are available in under ten minutes, supporting faster, on-site decision-making in treatment and justice settings. INBS is pursuing FDA approval and further entry into the U.S. market, where it currently operates in a Forensic Use Only capacity. The company has over 450 active accounts in 24 countries, targeting sectors such as healthcare, justice, and workplace safety. INBS partnered with SMARTOX, a U.S. distributor, to connect with stakeholders in criminal justice and addiction recovery. Intelligent Bio Solutions (NASDAQ: INBS),…

FridayJun 06, 2025 10:30 am

Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL

Soligenix’s HyBryte(TM) is a photodynamic therapy using synthetically manufactured hypericin, one of the most photoactive compounds available. The therapeutic potential of HyBryte(TM) has been demonstrated through multiple clinical trials, including a Phase 3 trial in early-stage CTCL patients. HyBryte(TM) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration and the European Medicines Agency. Cutaneous T-cell lymphoma (“CTCL”) is a rare and debilitating form of non-Hodgkin’s lymphoma that primarily affects the skin, posing both physical and emotional challenges for those diagnosed. With limited treatment options available and no definitive cure, the need for innovative, safe and effective…

FridayJun 06, 2025 10:00 am

More American Doctors are Relocating to Canada, Citing Federal Government Issues

As U.S. news outlets focus on the economic turmoil triggered by tariffs, another story is quietly developing. More doctors trained and working in the U.S. are relocating to Canada and the reasons they are giving rotate around the actions and policies of the Trump administration. Michael, a pseudonym, is one such doctor who left the U.S. to work in Canada. He says America is changing into a country that steps on the vulnerable and weak, in contrast to the training which makes physicians kind to individuals during their weakest moments. For him, the turning point was when a mob stormed…

ThursdayJun 05, 2025 11:15 am

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

The Kadima Neuropsychiatry Institute acquisition is part of NRx subsidiary HOPE Therapeutics’ model for a planned national clinic network, and is expected to immediately improve revenue and EBITDA for NRx and HOPE Therapeutics. HOPE aims to develop a network of up to 30 interventional psychiatry clinics by the end of 2025, with a $100 million pro forma run rate by YE 25. Kadima specializes in interventional psychiatry, and Kadima’s founder Dr. David Feifel, will join HOPE as Chief Medical Innovation Officer. NRx’s broader pipeline includes FDA-designated treatments for bipolar depression and acute suicidality. NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical…

ThursdayJun 05, 2025 10:00 am

Therapeutic Target Shows Promise in Preventing Cancer Resulting from Chronic Gut Inflammation

When inflammatory bowel disease becomes chronic, it is difficult to treat and comes with the likelihood of various complications, such as the onset of bowel cancer. This disease in its chronic form manifests as Crohn’s disease or ulcerative colitis. These diseases particularly impact young people. Early diagnosis followed by treatment is crucial in these cases. A recent study whose findings appeared in the Nature Immunology journal has unveiled a therapeutic target capable of significantly putting the brakes on the processes behind the chronic inflammation underlying inflammatory bowel disease. The research was conducted by a team based at Charite-Universitatsmedizin Berlin. Professor…

ThursdayJun 05, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Buprenorphine is a medication approved by the U.S. Food and Drug Administration (“FDA”) to treat opioid use disorder and chronic and severe pain Nutriband is developing a novel transdermal delivery system for buprenorphine, projected to reach peak annual sales of $70M – $130M The company’s AVERSA pipeline currently includes two main candidates: AVERSA(TM) Fentanyl and AVERSA(TM) Buprenorphine As the opioid epidemic continues to pose one of the most critical public health crises in the United States and around the world, the need for innovative, safer treatments has never been more urgent. One company, Nutriband (NASDAQ: NTRB), is aiming to transform how opioid-based therapies are administered and protected against…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Adageis Allows Healthcare Providers Maximum Value-Based Care Revenue with Simplicity and Visibility

Smart Hospitality: SkyTech Robots and the Future of U.S. Service Innovation Through AI

Lantern Pharma Inc. (NASDAQ: LTRN) Is ‘One to Watch’

Celebrity Announcements of Breast Cancer Underscore Increasing Prevalence in Younger Women

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Showcases Portable Drug Testing System at RISE25 as U.S. Expansion Advances

Soligenix Inc. (NASDAQ: SNGX) Offers Hope on the Horizon with HyBryte(TM) Treatment Targeting CTCL

More American Doctors are Relocating to Canada, Citing Federal Government Issues

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

Therapeutic Target Shows Promise in Preventing Cancer Resulting from Chronic Gut Inflammation

Nutriband Inc. (NASDAQ: NTRB) Advances Abuse-Deterrent Buprenorphine Therapy with AVERSA Technology

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search